Ginkgo Bioworks Forum: Community User: NILUIS

Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria https://finance.yahoo.com/news/synlogic-ginkgo-bioworks-announce-investigational-120000048.html Synlogic and Ginkgo collaboration generates clinical candidate SYNB1353 using Synlogic's proprietary Synthetic Biotic platform and Ginkgo Codebase SYNB1353 is the first investigational medicine developed from Ginkgo's platform to advance to IND-enabling studies Synlogic to present preclinical data on SYNB1353 at the upcoming International Congress of Inborn Errors of Metabolism 2021 meeting

Ginkgo Bioworks has received a Notice of Allowance for its US patent application 17/078,872 titled "BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS". https://patentcenter.uspto.gov/#!/applications/17078872/ifw/docs

ein Artikel über Arcaea, eines der ersten Unternehmen auf Basis der Ginkgo-Technologieplattform. Ich bin soooo gespannt auf viele weitere Launches in den nächsten 12-18 Monaten https://www.bizjournals.com/boston/news/2021/10/27/arcaea-ginkgo-bioworks-spinout-78m-series-a.html

‘Stock price speaks for itself’: Ginkgo CEO says after short-seller report https://www.cnbc.com/video/2021/10/28/stock-price-speaks-for-itself-ginkgo-ceo-says-after-short-seller-report.html Ginkgo co-founder and CEO, Jason Kelly, joins ‘Squawk on the Street’ ahead of the Ginkgo Bioworks Conference. Kelly discusses a recent short seller report, understanding the company logistics.

Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases https://www.globenewswire.com/news-release/2021/10/26/2320612/0/en/Selecta-Biosciences-and-Ginkgo-Bioworks-Announce-Partnership-to-Advance-Treatments-for-Orphan-and-Rare-Diseases.html Leveraging Ginkgo’s cell programming platform and Selecta’s ImmTOR platform to create potentially transformative enzymatic therapies Selecta gains rights to develop and commercialize select therapeutic enzymes from Ginkgo’s advanced organism engineering platform to treat select auto-immune diseases ...

https://www.gurufocus.com/news/1549161/ginkgo-bioworks-announces-participation-in-jefferies-gene-therapyediting-summit

Quest Diagnostics to Provide K-12 School COVID-19 Testing in Collaboration with Ginkgo Bioworks to Support Safer Classroom Learning in Texas for New Statewide School Testing Program https://www.prnewswire.com/news-releases/quest-diagnostics-to-provide-k-12-school-covid-19-testing-in-collaboration-with-ginkgo-bioworks-to-support-safer-classroom-learning-in-texas-for-new-statewide-school-testing-program-301403984.html Over 1,150 school districts in Texas can elect to participate in the testing program ResponsiveEd First Major School System to implement the Quest-Ginkgo solution ...

@Aktienmodel: wo ist das?

Bei mir ist Elon eingestiegen 🥰

👍

Baillie Gifford ist heute eingestiegen.. gutes Zeichen

Schöner Anstieg die letzten tage. Hoffe das die Gewinne halten.. es wäre noch besser, wenn gute news komme und den Anstieg untermauern.

Raymond James Initiates Coverage On Ginkgo Bioworks Holdings with Outperform Rating, Announces Price Target of $14.5 https://www.streetinsider.com/New+Coverage/Raymond+James+Starts+Ginkgo+Bioworks+Holdings+Inc+%28DNA%29+at+Outperform/19054270.html?classic=1

Eine gewisse Reaktion gab es ja: https://pub.webullfintech.com/us/news-html/b7cd6e8ee65245aaba4b573bea40b0f0.html?theme=2&color=2&hl=en&android_sdk_int=30&canary-version=&_v=1&sp=1&tickerId=950183699&disSymbol=DNA Gingko Bioworks CEO Responds To Short Seller Reports, Says Claim Co. Platform Is A Place For New Startups To Secure Capital, Launch Quickly Is Not A Problem ...

Was könnte der grund sein warum Ginkgo sich nicht zu den vorwürfen von scorpian äußert? Es wäre ja ein leichtes diese zu widerlegen, wenn sie nicht wahr sind

Ginkgo Bioworks rebounds as William Blair becomes bullish despite recent selloff https://seekingalpha.com/news/3752024-ginkgo-bioworks-rebounds-as-william-blair-becomes-bullish-despite-recent-selloff Ginkgo Bioworks (DNA +10.1%) has shed more than 20% after short seller Scorpion Capital called it “a colossal scam” in a report released on Wednesday. However, that has not discouraged William Blair to initiate its coverage with an outperform recommendation as the analyst Matthew Larew sees an opportunity in the platform-based company. “We expect Ginkgo to capture considerable value by democratizing cell programming,” Larew wrote, adding that the company’s platform makes synthetic biology more accessible for companies. Ginkgo Bioworks’ cell programming platform is designed to provide biotechnology applications addressing the needs of a wide range of markets from food and agriculture to industrial chemicals to pharmaceuticals. After the initial selloff on the short report, Ginkgo Bioworks shares recovered on Thursday after ARK Invest — run by notable fund manager Cathie Wood — doubled down on its position in the company. However, two consecutive sessions of declines followed.